This position paper on polio vaccines replaces the 2016 WHO position paper, and summarizes recent developments in the field.
First published in 2020, this toolkit is intended for clinicians working in acute care, managing adult and paediatric patients with acute respiratory infection, including severe pneumonia, acute respiratory distress syndrome, sepsis and septic shock. The main objective is to provide key tools for us...e in the care of critically ill patients – from hospital entry to hospital discharge.
The 2022 updated version includes new tools and adapted algorithms, checklists, memory aids for COVID-19 and influenza, and the latest clinical evidence regarding clinical management of SARI. It is intended to help clinicians care for SARI patients: from epidemiology of severe acute respiratory infections, screening and triage, infection prevention and control, monitoring of patients, laboratory diagnosis, principles of oxygen therapy and different types of ventilation (invasive and non-invasive), as well as antimicrobial and immunomodulator therapies, to ethical and quality of care assessments.
The first edition is availbel in Ukrainian and Russian
more
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.
More than two years since the first SARS-CoV-2 infections were reported, the COVID-19 pandemic remains an acute global emergency. In this Strategic Preparedness, Readiness and Response plan for 2022, WHO sets out a number of key strategic adjustments that, if implemented rapidly and consistently at ...national, regional, and global levels, will enable the world to end the acute phase of the pandemic.
more
Data on Infectious Diseases in Ukraine Now Available as a Free eBook to Help Medics and Relief Efforts During the War.
• Data on the 215+ infectious diseases endemic to Ukraine
• All published data on infections imported into Ukraine
To download the book, please click the button below and use... the coupon code EBOOKUKRAINE at checkout: The code will expire in 30 days.
March 2nd, 2022
more
26 de abril del 2022. La Organización Panamericana de la Salud presenta estas consideraciones con el fin de apoyar la toma de decisiones relativa al manejo de pacientes con COVID-19 en la Región de las Américas. Las recomendaciones tienen en cuenta la evidencia más reciente, el estado de vacunac...ión del paciente y los costos asociados con el uso de antivirales, anticuerpos monoclonales y otras intervenciones.
more
Weekly Epidemiological Record No 9, 2022, 97, 61–80
This position paper supersedes the 2016 publication, “Malaria vaccine: WHO position paper-2016.”1 It includes the updated WHO recommendations on the wider use of the RTS,S/AS01 vaccine for the reduction of malaria morbidity and mortality in ...children living in areas of moderate to high malaria transmission. It also incorporates findings from the evaluation of the WHO-coordinated Malaria Vaccine Implementation Programme (MVIP), recommended by SAGE and MPAG in 2015, and from additional studies since 2015.
This paper does not include findings on vaccine efficacy in infants first vaccinated at 6–12 weeks of age. Because of the lower vaccine efficacy observed in this age category, WHO did not recommend pilot implementation or RTS,S/AS01 vaccine introduction for these young infants. Recommendations2 on the use of RTS,S/AS01 vaccine were discussed by SAGE and MPAG during a joint session in October 2021; evidence presented at the meeting can be accessed at https://terrance.who.int/mediacentre/data/ sage/SAGE_eYB_Oct2021.pdf
more
Due to the particular Amazonian situation of vectorial transmission based mostly on the wild cycle of Trypanosoma cruzi with diversity of triatomine vectors involved in effective transmission, and the variety of eco-epidemiological situations that facilitate such transmission, the countries of the A...mazon agreed that the development and strengthening of preventive actions based on comprehensive surveillance and detection of effective vectorial transmission, based on mandatory notification of acute or chronic cases, was required. In addition, it was recommended that surveillance and prevention and/or vector control actioDue to the particular Amazonian situation of vectorial transmission based mostly on the wild cycle of Trypanosoma cruzi with diversity of triatomine vectors involved in effective transmission, and the variety of eco-epidemiological situations that facilitate such transmission, the countries of the Amazon agreed that the development and strengthening of preventive actions based on comprehensive surveillance and detection of effective vectorial transmission, based on mandatory notification of acute or chronic cases, was required.
more
The overall goal of surveillance, case investigation and contact tracing in this context is to stop human-to-human transmission to control the outbreak. The key objectives of surveillance and case investigation are to rapidly identify cases and clusters in order to provide optimal clinical care; to ...isolate cases to prevent further transmission; to identify, manage and follow up contacts to recognize early signs of infection; to protect frontline health workers; to identify risk groups; and to tailor effective control and prevention measures.
more
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals and other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2, ...including genomic sequencing, or are involved in making decisions on establishing or scaling up capability and capacity to detect and characterize circulating SARS-CoV-2 variants.
more
The African Region has been experiencing unprecedented health challenges due to the Coronavirus disease 2019 (COVID-19) pandemic, which have compounded the already difficult task the Region was facing in moving towards universal health coverage (UHC) attainment.
Cette première version des orientations evolutives relatives a la prise en charge clinique de la MVE contient quatre nouvelles recommandations concernant l’utilisation de traitements contre la MVE, y compris deux recommandations fortes en faveur de l’utilisation de thérapies à base d’antico...rps monoclonaux. Ce nouveau document est rédigé en vue d’accompagner des soins de support optimisés (oSoC) pour les procédures opérationnelles standards appliquees a la MVE (5, 6). Les orientations evolutives presentent des preuves de haute qualité concernant l’efficacite des traitements contre la MVE et les recommandations de l’OMS relatives leur utilisation.
more